Tin tức & Cập nhật
Lọc theo Chuyên ngành:
Upadacitinib shows promise for long-term AD treatment
Upadacitinib with topical corticosteroids shows good long-term efficacy and safety in patients with moderate-to-severe atopic dermatitis (AD), reports a recent follow-up analysis to the AD Up study.
Upadacitinib shows promise for long-term AD treatment
12 Mar 2022Adherence higher, discontinuation lower with ixekizumab vs secukinumab
Psoriasis patients treated with ixekizumab show better persistence and adherence over 24 months as well as a lower risk of discontinuation than those using secukinumab, reports a recent study that used real-world data.
Adherence higher, discontinuation lower with ixekizumab vs secukinumab
07 Mar 2022Ustekinumab safe, effective in Asians with severe plaque psoriasis
Ustekinumab, a human monoclonal antibody that binds to the p40 subunit of both interleukin (IL)-12 and IL-23, demonstrates effectiveness and safety in the treatment of multiethnic Asian patients with moderate to severe plaque psoriasis, according to a Singapore study.
Ustekinumab safe, effective in Asians with severe plaque psoriasis
04 Mar 2022Ligelizumab improves symptoms, QoL in patients with urticaria
In patients with chronic spontaneous urticaria (CSU) who remained symptomatic despite treatment, the monoclonal anti-immunoglobulin E antibody ligelizumab improved symptom control regardless of BHRA* status, as well as dermatology quality of life (QoL) regardless of angioedema status, findings from a phase IIb study have shown.
Ligelizumab improves symptoms, QoL in patients with urticaria
02 Mar 2022Worse joint pain in psoriasis patients with PsA boosts analgesic use
Psoriasis patients, especially those with concomitant psoriatic arthritis (PsA), suffer from worse joint pain, leading to higher analgesic use rates than the general population, a recent study has found.
Worse joint pain in psoriasis patients with PsA boosts analgesic use
27 Feb 2022Dual inhibition of LAG-3, PD-1: a new therapeutic target for advanced melanoma?
In the phase II/III RELATIVITY-047 trial evaluating dual checkpoint inhibition for advanced melanoma, a new fixed-dose combination comprising the LAG-3 inhibitor relatlimab and the PD-1 inhibitor nivolumab fared better than nivolumab monotherapy.